Vermillion (NASDAQ:VRML) Downgraded by BidaskClub
Shares of VRML traded up $0.30 during midday trading on Friday, hitting $3.60. The company had a trading volume of 1,279,297 shares, compared to its average volume of 1,061,370. The company’s 50 day moving average price is $2.20 and its 200 day moving average price is $1.16. The stock has a market cap of $321.35 million, a price-to-earnings ratio of -21.18 and a beta of 3.47. Vermillion has a 52 week low of $0.35 and a 52 week high of $5.61. The company has a quick ratio of 2.49, a current ratio of 2.51 and a debt-to-equity ratio of 0.20.
Vermillion (NASDAQ:VRML) last released its earnings results on Thursday, March 26th. The company reported ($0.03) earnings per share for the quarter. Vermillion had a negative return on equity of 155.25% and a negative net margin of 307.31%. The company had revenue of $1.31 million during the quarter.
Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.
Featured Article: What is a good rate of return for a mutual fund?
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.